• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CD44s、CD44v6和CD44v10在局限性前列腺癌中的表达谱:对根治性前列腺切除术后预后结果的影响

Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomy.

作者信息

Tei Hiromoto, Miyake Hideaki, Harada Ken-ichi, Fujisawa Masato

机构信息

Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.

Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.

出版信息

Urol Oncol. 2014 Jul;32(5):694-700. doi: 10.1016/j.urolonc.2013.12.002. Epub 2014 Jan 24.

DOI:10.1016/j.urolonc.2013.12.002
PMID:24468288
Abstract

OBJECTIVES

To investigate the expression of CD44 standard form (CD44s) and 2 major variant exons (CD44v6 and CD44v10) in localized prostate cancer (PC) to determine the prognostic significance of these markers following radical prostatectomy (RP).

MATERIALS AND METHODS

Expression levels of CD44s, CD44v6, and CD44v10 in RP specimens from 160 consecutive patients with clinically localized PC were evaluated by immunohistochemical staining.

RESULTS

Of these 3 markers, expression level of CD44v6 was closely associated with several conventional prognostic factors. Univariate analysis identified CD44v6 expression in addition to serum prostate-specific antigen level, Gleason score, seminal vesicle invasion, and surgical margin status as significant predictors for biochemical recurrence (BR). Of these significant factors, CD44v6 expression, serum prostate-specific antigen level, and surgical margin status appeared to be independently associated with BR on multivariate analysis. We observed significant differences in BR-free survival according to the positive numbers of these 3 independent factors; i.e., BR occurred in 0 (0%) of 42 patients who had negative results for risk factors, 9 (16.7%) of 54 who had positive results for 1 risk factor, and 31 (48.4%) of 64 who had positive results for 2 or 3 risk factors.

CONCLUSIONS

Assessment of the expression levels of CD44v6 in RP specimens in addition to conventional prognostic parameters would contribute to the accurate prediction of the biochemical outcome in patients with localized PC who underwent RP.

摘要

目的

研究CD44标准型(CD44s)及2个主要可变外显子(CD44v6和CD44v10)在局限性前列腺癌(PC)中的表达情况,以确定这些标志物在根治性前列腺切除术(RP)后的预后意义。

材料与方法

通过免疫组织化学染色评估160例连续的临床局限性PC患者RP标本中CD44s、CD44v6和CD44v10的表达水平。

结果

在这3种标志物中,CD44v6的表达水平与多个传统预后因素密切相关。单因素分析确定,除血清前列腺特异性抗原水平、Gleason评分、精囊侵犯及手术切缘状态外,CD44v6表达是生化复发(BR)的重要预测指标。在这些重要因素中,多因素分析显示CD44v6表达、血清前列腺特异性抗原水平及手术切缘状态似乎与BR独立相关。根据这3个独立因素的阳性数量,我们观察到无BR生存存在显著差异;即,42例危险因素结果为阴性的患者中0例(0%)发生BR,54例有1个危险因素结果为阳性的患者中9例(16.7%)发生BR,64例有2个或3个危险因素结果为阳性的患者中31例(48.4%)发生BR。

结论

除传统预后参数外,评估RP标本中CD44v6的表达水平将有助于准确预测接受RP的局限性PC患者的生化结局。

相似文献

1
Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomy.CD44s、CD44v6和CD44v10在局限性前列腺癌中的表达谱:对根治性前列腺切除术后预后结果的影响
Urol Oncol. 2014 Jul;32(5):694-700. doi: 10.1016/j.urolonc.2013.12.002. Epub 2014 Jan 24.
2
Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy.上皮-间充质转化标志物在局限性前列腺癌中的表达模式:根治性前列腺切除术后临床病理结局的意义。
BJU Int. 2013 Jan;111(1):30-7. doi: 10.1111/j.1464-410X.2012.11551.x. Epub 2012 Oct 26.
3
Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.前列腺癌中潜在分子标志物的表达:与接受根治性前列腺切除术患者的临床病理结局的相关性。
Urol Oncol. 2010 Mar-Apr;28(2):145-51. doi: 10.1016/j.urolonc.2008.08.001. Epub 2008 Oct 10.
4
Expression Profile of Autophagy-related Markers in Localized Prostate Cancer: Correlation With Biochemical Recurrence After Radical Prostatectomy.局限性前列腺癌中自噬相关标志物的表达谱:与前列腺癌根治术后生化复发的相关性
Urology. 2015 Jun;85(6):1424-30. doi: 10.1016/j.urology.2015.03.006. Epub 2015 Apr 14.
5
Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.辅助治疗初治患者根治性前列腺切除术后切缘阳性对前列腺特异抗原失败的影响。
BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.
6
The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.CD44 亚型在接受根治性前列腺切除术的前列腺癌患者中的预后价值。
Clin Cancer Res. 1997 May;3(5):805-15.
7
Prognostic value of CD44 standard, variant isoforms 3 and 6 and -catenin expression in local prostate cancer treated by radical prostatectomy.CD44标准型、变异体3和6以及β-连环蛋白表达在接受根治性前列腺切除术的局限性前列腺癌中的预后价值
Eur Urol. 2000 Nov;38(5):555-62. doi: 10.1159/000020355.
8
Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.细胞周期蛋白p27(kip1)、MIB-1以及细胞黏附蛋白CD44s在接受手术治疗的前列腺癌患者中的预后价值。
J Urol. 2000 Dec;164(6):2156-61.
9
Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.高迁移率族蛋白 B1 的过表达与根治性前列腺切除术后患者的不良预后相关。
BJU Int. 2012 Dec;110(11 Pt C):E1125-30. doi: 10.1111/j.1464-410X.2012.11277.x. Epub 2012 Jun 6.
10
Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.透明质酸、透明质酸酶(HYAL-1)、CD44v6和微血管密度对前列腺癌的预后潜力比较。
Int J Cancer. 2004 Oct 20;112(1):121-9. doi: 10.1002/ijc.20368.

引用本文的文献

1
Extracellular matrix and its therapeutic potential for cancer treatment.细胞外基质及其在癌症治疗中的治疗潜力。
Signal Transduct Target Ther. 2021 Apr 23;6(1):153. doi: 10.1038/s41392-021-00544-0.
2
Targeting prostate cancer stem-like cells by an immunotherapeutic platform based on immunogenic peptide-sensitized dendritic cells-cytokine-induced killer cells.基于免疫原性肽致敏树突状细胞-细胞因子诱导的杀伤细胞的免疫治疗平台靶向前列腺癌干细胞样细胞。
Stem Cell Res Ther. 2020 Mar 17;11(1):123. doi: 10.1186/s13287-020-01634-6.
3
CD44 splice isoform switching determines breast cancer stem cell state.
CD44 剪接异构体转换决定乳腺癌干细胞状态。
Genes Dev. 2019 Feb 1;33(3-4):166-179. doi: 10.1101/gad.319889.118. Epub 2019 Jan 28.
4
Stem-like and highly invasive prostate cancer cells expressing CD44v8-10 marker originate from CD44-negative cells.表达CD44v8-10标志物的干细胞样且具有高度侵袭性的前列腺癌细胞起源于CD44阴性细胞。
Oncotarget. 2018 Jul 20;9(56):30905-30918. doi: 10.18632/oncotarget.25773.
5
Concise Review: Prostate Cancer Stem Cells: Current Understanding.简明综述:前列腺癌干细胞:当前认识。
Stem Cells. 2018 Oct;36(10):1457-1474. doi: 10.1002/stem.2859. Epub 2018 Aug 27.
6
PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma.前列腺腺癌根治术后组织中 PanCD44 的免疫组化检测
Biomed Res Int. 2018 Feb 26;2018:2061268. doi: 10.1155/2018/2061268. eCollection 2018.
7
Targeting aggressive prostate cancer-associated CD44v6 using phage display selected peptides.利用噬菌体展示筛选的肽靶向侵袭性前列腺癌相关的CD44v6
Oncotarget. 2017 Sep 30;8(49):86747-86768. doi: 10.18632/oncotarget.21421. eCollection 2017 Oct 17.
8
Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer.前列腺癌中当前的干细胞生物标志物及其功能机制
Int J Mol Sci. 2016 Jul 19;17(7):1163. doi: 10.3390/ijms17071163.
9
SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis.SOX2促进前列腺癌主要肿瘤进展基因,并且是淋巴结转移的功能性生物标志物。
Oncotarget. 2016 Mar 15;7(11):12372-85. doi: 10.18632/oncotarget.6029.
10
sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients.E-钙黏蛋白可作为前列腺癌患者的诊断和预测指标。
J Exp Clin Cancer Res. 2015 May 14;34(1):43. doi: 10.1186/s13046-015-0161-6.